SGS Life Science Services Opens Center of Excellence for Biophysical Analysis - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

SGS Life Science Services Opens Center of Excellence for Biophysical Analysis


SGS Life Science Services has completed the development of a Center for Excellence for biophysical analysis of biopharmaceutical products in its SGS M-Scan facility in Wokingham, the United Kingdom.

The biophysical analysis group is lead by Dr.Iñigo Rodriguez-Mendieta, who along with his team, provides expertise in higher order structure analysis. The team can perform aggregation analysis, secondary/tertiary structural analysis, and thermal stability assessment and comparison. The new center complements the company's recent investment, announced in March 2013, to develop integrated formulation and stability testing services at the Wokingham facility, slated for completion in the fourth quarter 2013 and to be fully validated by early 2014.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here